NASDAQ: OCSOculis Holding Ag Stock
$19.57-0.07 (-0.36%)
Updated Mar 21, 2025
OCS Price
$19.57
Fair Value Price
N/A
Market Cap
$854.47M
52 Week Low
$10.55
52 Week High
$23.08
P/E
-8.31x
P/B
10.48x
P/S
935.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$762.22k
Earnings
-$95.31M
Gross Margin
100%
Operating Margin
-12,434.11%
Profit Margin
-12,503.9%
Debt to Equity
0.64
Operating Cash Flow
-$53M
Beta
0.13
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OCS Overview
European Biotech Acquisition Corp. is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations. It targets opportunities in the life sciences industry in Europe. European Biotech Acquisition was incorporated in 2021 and is based in Amsterdam, the Netherlands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OCS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OCS
Ranked#239 of 483
Ranked#239 of 483
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.49 | A | |
| $138.76 | A | |
| $7.75 | A |
Be the first to know about important OCS news, forecast changes, insider trades & much more!
OCS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OCS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OCS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OCS is poor value based on its book value relative to its share price (10.48x), compared to the US Biotechnology industry average (4.69x)
P/B vs Industry Valuation
OCS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more OCS due diligence checks available for Premium users.
Valuation
OCS fair value
Fair Value of OCS stock based on Discounted Cash Flow (DCF)
Price
$19.57
Fair Value
$0.29
Overvalued by
6,587.78%
OCS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OCS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.31x
Industry
-110.14x
Market
31.55x
OCS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.48x
Industry
4.69x
OCS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OCS's financial health
Profit margin
Revenue
$3.3k
Net Income
-$31.8M
Profit Margin
-955,166.7%
OCS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OCS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$133.7M
Liabilities
$52.2M
Debt to equity
0.64
OCS's short-term assets ($116.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OCS's short-term assets ($116.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OCS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.5M
Investing
-$1.2M
Financing
$3.0M
OCS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OCS vs Biotech Stocks
Oculis Holding Ag Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.